Heart failure & cardiomyopathies
Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial
Authors' conclusion
Patients with LVEF>40% and recent WHF had greater reduction in NT-proBNP with sac/val vs val, regardless of the degree of structural abnormalities. There was no difference in the effects of sac/val on efficacy endpoints across structural abnormality group. Patients with both LVH and LAE had higher odds for hyperkalemia with sac/val.
Study context
- Population
- Patients with LVEF>40% and worsening HFwith left ventricular hypertrophy (LVH) and left atrial enlargement (LAE) data
- Participants
- 454 patients
- Comparison
- Sacubitril/valsartan vs valsartan, by degree of structural abnormalities
- Both LVH and LAEn = 157
- Either LVH or LAEn = 178
- Neither LVH nor LAEn = 119
- Primary endpoint
- Time-averaged proportional change in NT-proBNP from baseline
- Follow-up
- Weeks 4 and 8
Primary result
As reported in the abstract
NT-proBNP reduction, sac/val vs val, by structural abnormality group
- Greater reduction in NT-proBNP with sac/val vs val, consistent across groups
- P interaction = 0.705
Secondary outcomes
Other efficacy endpoints (recurrent CV composite: HF hospitalizations, urgent HF visits, CV death)
- No significant interaction between treatment and degree of structural abnormalities
Safety
| Outcome | OR |
|---|---|
| Hyperkalemia with sac/val, both LVH and LAESac/val vs Val · Both LVH and LAE | 2.41 |
- Hyperkalemia with sac/val, both LVH and LAE: P interaction = 0.024
Original publication
Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial. Am Heart J. Published 22 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →